Triple

Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).

Phrase: PD-1 | Statement: [programmed death-ligand 1, bindsTo, PD-1]

Target entity: PD-1
Context triple: [programmed death-ligand 1, bindsTo, PD-1]

• A. programmed death-ligand 1
  Programmed death-ligand 1 (PD-L1) is an immune checkpoint protein expressed on various cells that suppresses T-cell activity by engaging PD-1, enabling tumors to evade immune surveillance.
• B. Betatakin
  Betatakin is an ancient Ancestral Puebloan cliff dwelling carved into a sandstone alcove in what is now northern Arizona.
• C. Leqembi
  Leqembi is an Alzheimer’s disease drug (lecanemab) that targets amyloid-beta plaques to slow cognitive decline in early-stage patients.
• D. Kymriah
  Kymriah is a pioneering CAR-T cell therapy used to treat certain types of blood cancers by genetically modifying a patient’s own immune cells to target and destroy malignant cells.
• E. Keytruda
  Keytruda is a widely used immunotherapy cancer drug (pembrolizumab) that works by blocking the PD-1 pathway to help the immune system attack tumors.
• F. None of above. chosen
• G. Unsure - the case is ambiguous/there is not enough information to decide.

Generate a one-sentence description of the target entity. 
You are given a context triple in the form (subject, predicate, object), where the object is the target entity. 
# Instructions
Use the triple to infer relevant information about the entity. Describe the entity based on what is most defining, well-known. 
Avoid repeating the information from the triple, unless really essential.
# Response Format
Return only the sentence: "Description: [one-sentence description of the target entity]"

Entity: PD-1
Triple: [programmed death-ligand 1, bindsTo, PD-1]

PD-1 is an inhibitory immune checkpoint receptor on T cells that downregulates immune responses and is a key target of cancer immunotherapy.

Target entity: PD-1
Target entity description: PD-1 is an inhibitory immune checkpoint receptor on T cells that downregulates immune responses and is a key target of cancer immunotherapy.

• A. programmed death-ligand 1
  Programmed death-ligand 1 (PD-L1) is an immune checkpoint protein expressed on various cells that suppresses T-cell activity by engaging PD-1, enabling tumors to evade immune surveillance.
• B. Betatakin
  Betatakin is an ancient Ancestral Puebloan cliff dwelling carved into a sandstone alcove in what is now northern Arizona.
• C. Leqembi
  Leqembi is an Alzheimer’s disease drug (lecanemab) that targets amyloid-beta plaques to slow cognitive decline in early-stage patients.
• D. Kymriah
  Kymriah is a pioneering CAR-T cell therapy used to treat certain types of blood cancers by genetically modifying a patient’s own immune cells to target and destroy malignant cells.
• E. Keytruda
  Keytruda is a widely used immunotherapy cancer drug (pembrolizumab) that works by blocking the PD-1 pathway to help the immune system attack tumors.
• F. None of above. chosen